DOCSLIB.ORG

Corticosteroids

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Corticosteroids Corticosteroids Corticosteroids are a class of steroid hormones that are produced in the adrenal cortex. Corticosteroids are involved in a wide range of physiologic systems such as: Stress response Immune response and regulation of inflammation Carbohydrate metabolism Protein catabolism Blood electrolyte levels, and Behavior Glucocorticoids such as cortisol control carbohydrate, fat and protein metabolism and are anti-inflammatory by preventing phospholipid release, decreasing eosinophil action and a number of other mechanisms. Mineralocorticoids such as aldosterone control electrolyte and water levels, mainly by promoting sodium retention in the kidney. Common natural hormones: Corticosterone Cortisone Aldosterone Classification of Corticosteroids: Group A (short to medium acting glucocorticoids): Hydrocortisone, Hydrocortisone acetate, Cortisone acetate, Tixocortol pivalate, Prednisolone, Methylprednisolone, and Prednisone. Group B: Triamcinolone acetonide, Mometasone, Amcinonide, Budesonide, Desonide, Fluocinonide, Fluocinolone acetonide, and Halcinonide. Group C: Betamethasone, Sodium phosphate, Dexamethasone, Dexamethasone sodium phosphate, and Fluocortolone. Group D: Hydrocortisone-17-butyrate, Betamethasone valerate, Betamethasone dipropionate, Prednicarbate, and Fluprednidene acetate. Routes of administration of Corticosteroids: 1. Topical steroid for use topically on the skin, eye, and mucous membranes. 2. Inhaled steroids for use to treat the nasal mucosa, sinuses, bronchii, and lungs. 3. Oral forms such as prednisone and prednisolone. 4. Systemic forms available in injectibles for use intravenously and parenteral routes Glucocorticoids: Are Hydrocortisone, cortisone,corticosterone. Hydrocortisone is the important glucocorticoid secreted in man. Pharmacological Actions: 1. Carbohydrate metabolism: They promote gluconeogenesis and deposition of glycogen in the liver, but utilization of glucose is inhibited. 2. Protein metabolism: Increase the breakdown of protein. The aminoacids so produced support gluconeogenesis. 3. Fat metabolism: They increase the mobilization of fat from peripheral fat depots. On prolonged administration the produce a redistribution of fat in the body. There is loss of fat from extremities and it is deposited in the neck, face etc. 4. Electrolyte and water metabolism: Hydrocortisone increases sodium retention and potassium excretion. Sodium retention leads to water retention and edema. This may produce rise in blood pressure. 5. Calcium Metabolism: They increase calcium excretion. Absorption of calcium from the gut is decreased. They also stimulate breakdown of the protein matrix of bone. All these effects leads to osteoporosis. 6. Hematological Actions: They decrease the production of eosinophils and lymphocytes, but they stimulate erythropoiesis and the production of polymorphonuclear leucocytes. 7. Muscles: Muscles weakness seen in Addison’s disease is corrected by glucocorticoids. 8. GIT: They stimulate the secretion of pepsin and hydrochloric acid of gastric juice. 9. Anti-inflammatory effects: They inhibit inflammatory response caused by bacterial,chemical and immunological factors. The anti-inflammatory effect is due to a decrease in capillary permeability and stabilization of lysosome membrane. 10.Antiallergic effect: They suppress allergic reactions such as asthma. They also reduce the formation of antibodies and cause shrinkage of lymphatic tissue, 11.CNS: They have an effect on psyche. Large doses can produce elevation of mood, euphoria restlessness. 12.Miscellaneous: They have an uricosuric and non-specific antipyretic effects. Adverse Reactions: 1. Cushing’s syndrome characterised by rounding of face. 2. Sodium retention and edema. 3. Muscular weakness due to potassium loss. 4. Gain in weight due to fluid retention and fat deposition. 5. Glycosuria and aggravation of diabetes. 6. Hypertension and congestive cardiac failure. 7. Androgenic effects like hirsutism and amenorrhea. 8. Psychological effects like euphoria and excitation. 9. Osteoporosis and spontaneous fracture of bones. 10.Peptic ulcer, perforation and haemorrhage. 11.Increased susceptibility to infections. Therapeutic uses: 1. Substitution therapy in adrenal insufficiency as in Addison’s disease. 2. Mesenchymal diseases like rheumatoid arthritis and rhematic fever. 3. Anti-inflammatory effect as in case of gout. 4. Allergic diseases like asthma 5. Skin diseases like exfoliative dermatitis, contract dermatitis and psoriasis. 6. Diseases of eye involving inflammatory and exudative phases. 7. Haemopoietic diseases like autoimmune haemolytic anemia, thrombocytopenia, agranulocytosis. 8. Neoplastic diseases like myeloma, lymphoid leukemia and Hodgkin’s disease. 9. Gastointestinal diseases like ulcerative colitis. 10.Hepatic diseases like acute viral hepatitis. Synthetic Glucocorticoids: The natural glucocorticoids(i.e. hydrocortisone, cortisone and corticosterone) have undesirable effects. The most important of them are salt and water retention. The synthetic glucocoticoids have less salt and water retaining effect and anti- inflammatory effect. The synthetic glucocoticoids are Prednisone, Prednisolone, triamcinolone, paramethasone, dexamethasone and betamethasone. The pharmacological action and toxicities of these compounds are similar to those of natural glucocorticoids, but these compounds do not have a mineralocorticoid action. Advantages: Effectiveness in smaller doses. Easy diffusion into the tissues. Possibility to prepare esters suitable for topical application and injection into tissues. Mineralocorticoids: The natural mineralocorticoids are aldosterone and desoxycorticosterone. The action of these two compounds are almost similar but aldosterone is thirty times more potent than desoxycorticosterone. Fludrocortisone is a synthetic mineralocorticoid and is commonly used for salt retaining effects. Pharmacological Actions: Both aldosterone and desoxycorticosterone induce reabsorption of sodium by the renal tubules They increase urinary loss of potassium. They induce sodium reabsorption in the sweat and salivary glands also. Excessive levels of aldosterone(as produced by tumours) leads to hypernatremia, hypokalemia, increased plasma volume and hypertension. In case of aldosterone deficiency there is hyperkalemia, decrease in blood volume and collapse. Uses: Only in the management of Addison’s disease..
Load more

Recommended publications
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Pharmacy and Poisons Act 1979
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,544,192 B2 Eaton Et Al
    US007544192B2 (12) United States Patent (10) Patent No.: US 7,544,192 B2 Eaton et al. (45) Date of Patent: Jun. 9, 2009 (54) SINUS DELIVERY OF SUSTAINED RELEASE 5,443,498 A 8, 1995 Fontaine THERAPEUTICS 5,512,055 A 4/1996 Domb et al. 5,664,567 A 9, 1997 Linder (75) Inventors: Donald J. Eaton, Woodside, CA (US); 5,693,065. A 12/1997 Rains, III Mary L. Moran, Woodside, CA (US); 5,792,100 A 8/1998 Shantha Rodney Brenneman, San Juan Capistrano, CA (US) (73) Assignee: Sinexus, Inc., Palo Alto, CA (US) (Continued) (*) Notice: Subject to any disclaimer, the term of this FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 U.S.C. 154(b) by 992 days. WO WOO1/02024 1, 2001 (21) Appl. No.: 10/800,162 (22) Filed: Mar 12, 2004 (Continued) (65) Prior Publication Data OTHER PUBLICATIONS US 2005/OO437O6A1 Feb. 24, 2005 Hosemann, W. et al. (Mar. 2003, e-pub. Oct. 10, 2002). “Innovative s Frontal Sinus Stent Acting as a Local Drug-Releasing System.' Eur: Related U.S. Application Data Arch. Otorhinolarynolo. 260:131-134. (60) Provisional application No. 60/454,918, filed on Mar. (Continued) 14, 2003. Primary Examiner Kevin C Sirmons (51) Int. Cl Assistant Examiner Catherine NWitczak A. iM sI/00 (2006.01) (74) Attorney, Agent, or Firm Morrison & Foerster LLP (52) U.S. Cl. ........................ 604/506; 604/510; 604/514 (57) ABSTRACT (58) Field of Classification Search .............. 604/93.01, 604/891.1. 890.1, 57, 59-64, 510, 514,506; S lication file f 606/196 The invention provides biodegradable implants for treating ee application file for complete search history.
    [Show full text]
  • Using F-NMR and H-NMR for Analysis of Glucocorticosteroids in Creams
    KTH Royal Institute of Technology School of Chemical Engineering Degree project, in KD203X, second level, 2010 Using 19F-NMR and 1H-NMR for Analysis of Glucocorticosteroids in Creams and Ointments - Method Development for Screening, Quantification and Discrimination Angelica Lehnström Supervisors Monica Johansson, Medical Products Agency Ian McEwen, Medical Products Agency Examiner István Furó, Royal Institute of Technology Abstract Topical treatment containing undeclared corticosteroids and illegal topical treatment with corticosteroid content have been seen on the Swedish market. In creams and ointments corticosteroids in the category of glucocorticosteroids are used to reduce inflammatory reactions and itchiness in the skin. If the inflammation is due to bacterial infection or fungus, complementary treatment is necessary. Side effects of corticosteroids are skin reactions and if used in excess suppression of the adrenal gland function. Therefore the Swedish Medical Products Agency has published related warnings to make the public aware. There are many similar structures of corticosteroids where the anti-inflammatory effect is depending on substitutions on the corticosteroid molecular skeleton. In legal creams and ointments they can be found at concentrations of 0.025 - 1.0 %, where corticosteroids with fluorine substitutions usually are found at concentrations up to 0.1 % due to increased potency. At the Medical Products Agency 19F-NMR and 1H-NMR have been used to detect and quantify corticosteroid content in creams and ointments. Nuclear Magnetic Resonance, NMR, is an analytical technique which is quite sensitive and can have a relative short experimental time. The low concentration of corticosteroids makes the signals detected in NMR small and in 1H-NMR the signals are often overlapped by signals from the matrix.
    [Show full text]
  • X-Ray Microscope Röntgenstrahlmikroskop Microscope À Rayons X
    (19) TZZ ___T (11) EP 2 511 844 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: G06F 21/00 (2013.01) G21K 7/00 (2006.01) 12.08.2015 Bulletin 2015/33 (21) Application number: 12164870.3 (22) Date of filing: 10.10.2007 (54) X-ray microscope Röntgenstrahlmikroskop Microscope à rayons X (84) Designated Contracting States: • Stewart, Jeffrey, J. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Los Alamos, NM 87544 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • Harris, Michael, N. SI SK TR Los Alamos, NM 87544 (US) • Burrell, Anthony, K. (30) Priority: 10.10.2006 US 850594 P Los Alamos, NM 87544 (US) (43) Date of publication of application: (74) Representative: Lorente Berges, Ana 17.10.2012 Bulletin 2012/42 A2 Estudio Legal C/ Hermosilla Nº 59, bajo izq (62) Document number(s) of the earlier application(s) in 28001 Madrid (ES) accordance with Art. 76 EPC: 07874491.9 / 2 084 519 (56) References cited: WO-A1-97/25614 US-A1- 2003 023 562 (73) Proprietor: XRpro Sciences, Inc. US-A1- 2004 128 518 US-A1- 2004 235 059 Los Alamos, NM 87544 (US) US-A1- 2005 015 596 (72) Inventors: • POTTS PHILIP J ET AL: "Atomic spectrometry • Birnbaum, Eva, R. update__X-ray fluorescence spectrometry", Los Alamos, NM 87544 (US) JOURNAL OF ANALYTICAL ATOMIC • Koppisch, Andrew, T. SPECTROMETRY, ROYAL SOCIETY OF Los Alamos, NM 87544 (US) CHEMISTRY, vol. 21, no.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,132,087 B2 Lichter Et Al
    US009132087B2 (12) United States Patent (10) Patent No.: US 9,132,087 B2 Lichter et al. (45) Date of Patent: Sep. 15, 2015 (54) AURIS FORMULATIONS FOR TREATING (52) U.S. Cl. OTC DISEASES AND CONDITIONS CPC ................. A61 K9/0046 (2013.01); A61 K9/06 (2013.01); A61K 9/14 (2013.01) (75) Inventors: Jay Lichter, Rancho Santa Fe, CA (US); (58) Field of Classification Search Andrew M. Trammel, Olathe, KS (US); Fabrice Piu, San Diego, CA (US); Luis CPC .......... A61 K9/0046; A61 K9/06; A61 K9/14 A. Dellamary, San Marcos, CA (US); See application file for complete search history. Qiang Ye, San Diego, CA (US); Carl (56) References Cited Lebel, Malibu, CA (US); Michael Christopher Scaife, Los Altos, CA U.S. PATENT DOCUMENTS (US); Jeffrey P. Harris, La Jolla, CA 4,478,822 A 10, 1984 Haslam et al. (US) 4,530,840 A 7, 1985 Tice et al. 4,900,552 A 2f1990 Sanvordeker et al. (73) Assignees: OTONOMY, INC., San Diego, CA 4,938,763. A 7, 1990 Dunn et al. 4,968,507 A * 1 1/1990 Zentner et al. ................ 424/465 (US): THE REGENTS OF THE 5,292,516 A 3/1994 Viegas et al. UNIVERSITY OF CALIFORNLA, 5,324,519 A 6/1994 Dunn et al. Oakland, CA (US) 5,451,399 A 9/1995 Gimbrone, Jr. et al. 5,503,848 A 4/1996 Perbellini et al. (*) Notice: Subject to any disclaimer, the term of this 5,702,716 A 12/1997 Dunn et al. patent is extended or adjusted under 35 5,714,167 A 2f1998 Milstein et al.
    [Show full text]
  • Poison Or Antibiotic? a Guide to "Class" Entries
    Poison or Antibiotic? A Guide to “Class” Entries Preface Most entries in the Poisons List, i.e. the Schedule 10, and the Schedules 1, 2 and 3 to the Pharmacy and Poisons Regulations (Cap. 138A) are in the form of individual drugs and their salts, e.g. “Abacavir; its salts”. However, some entries are in the form of a “class”, e.g. “Barbituric acid; its salts; its derivatives …”. In such cases, it is not always clear which drugs are members of the class (e.g. amobarbital, barbital, pentobarbital, phenobarbital, etc. are poisons, being derivatives of barbituric acid). Likewise, the Antibiotics Ordinance (Cap. 137) applies to the substances specified in Schedule 1 to the Antibiotics Regulations, to their salts and derivatives, and to the salts of such derivatives. Again, it is not always clear which drugs are derivatives of an antibiotic named in the Schedule (e.g. demeclocycline, doxycycline, tigecycline, etc. are antibiotics, being derivatives of “Tetracycline” named in the Schedule). This Guide provides a list of such drugs which are available as registered pharmaceutical products in Hong Kong. Drugs which are not available as registered pharmaceutical products in Hong Kong are also included in this Guide as far as possible. It should be noted that it is not possible to compile a complete list of all these drugs, simply because there is no limit to the number of “derivatives” a parent chemical can have. This Guide should be read in conjunction with the Schedules 1, 2, 3, and 10 to the Pharmacy and Poisons Regulations, and Schedule 1 to the Antibiotics Regulations, if the poison/antibiotic classification of a particular pharmaceutical product is to be determined.
    [Show full text]
  • Poisons List (Jersey) Order 1986
    POISONS LIST (JERSEY) ORDER 1986 Revised Edition 20.775.60 Showing the law as at 1 January 2011 This is a revised edition of the law Poisons List (Jersey) Order 1986 Arrangement POISONS LIST (JERSEY) ORDER 1986 Arrangement Article 1 Poisons List ..................................................................................................... 5 2 Citation ............................................................................................................ 5 SCHEDULE 6 THE POISONS LIST 6 PART 1 6 PART 2 50 PART 3 52 Supporting Documents ENDNOTES 53 Table of Legislation History......................................................................................... 53 Table of Renumbered Provisions ................................................................................. 53 Table of Endnote References ....................................................................................... 53 Revised Edition – 1 January 2011 Page - 3 20.775.60 Poisons List (Jersey) Order 1986 Article 1 POISONS LIST (JERSEY) ORDER 19861 THE HEALTH AND SOCIAL SERVICES COMMITTEE in pursuance of Article 8 of the Pharmacy and Poisons (Jersey) Law 1952,2 orders as follows – Commencement [see endnotes] 1 Poisons List The list of substances which are to be treated as poisons for the purposes of the Poisons (Jersey) Law 1952,3 shall be as set out in the Schedule to this Order.4 2 Citation This Order may be cited as the Poisons List (Jersey) Order 1986. Revised Edition – 1 January 2011 Page - 5 20.775.60 SCHEDULE Poisons List (Jersey) Order 1986 SCHEDULE
    [Show full text]
  • ( 12 ) United States Patent
    US010292951B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 ,292 , 951 B2 Glick et al. (45 ) Date of Patent: May 21, 2019 ( 54 ) METHODS AND COMPOSITIONS FOR (58 ) Field of Classification Search TREATING CONDITIONS ASSOCIATED CPC . .. .. .. .. A61K 31 / 167 WITH AN ABNORMAL INFLAMMATORY See application file for complete search history . RESPONSES (56 ) References Cited (71 ) Applicant: First Wave Bio , Inc ., Ann Arbor, MI U . S . PATENT DOCUMENTS (US ) 3 , 079 ,297 A 2 / 1963 Schraufstatter et al. (72 ) Inventors : Gary D . Glick , Ann Arbor, MI (US ) ; 5 ,663 , 155 A * 9 / 1997 McCaffrey .. A61K 31/ 70 Luigi Franchi, Ann Arbor, MI (US ) ; 514 / 45 Giancarlo Santus, Milan ( IT ) ( Continued ) ( 73 ) Assignee : First Wave Bio , Inc ., Ann Arbor , MI FOREIGN PATENT DOCUMENTS (US ) CN 105063018 A * 11 / 2015 ( * ) Notice : Subject to any disclaimer, the term of this EP 0938338 9 /2009 patent is extended or adjusted under 35 (Continued ) U . S . C . 154 (b ) by 0 days . OTHER PUBLICATIONS (21 ) Appl . No. : 15 /255 , 102 CureZone .org ( http : / /www . curezone .org / forums/ fm .asp ? i = ( 22 ) Filed : Sep . 1 , 2016 2146880 # i, accessed May 15 , 2017, dated Feb . 2 , 2014 ). * (Continued ) (65 ) Prior Publication Data Primary Examiner — Benjamin J Packard US 2017 /0056347 A1 Mar. 2 , 2017 ( 74 ) Attorney , Agent, or Firm — Fish & Richardson P . C . (57 ) ABSTRACT This disclosure features chemical entities ( e . g ., a compound Related U . S . Application Data exhibiting activity as a mitochondrial uncoupling agent or a (60 ) Provisional application No . 62/ 213 ,016 , filed on Sep . pharmaceutically acceptable salt and / or hydrate and /or coc 1 , 2015 , provisional application No .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0075958A1 Bistuer Et Al
    US 20090075958A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0075958A1 Bistuer et al. (43) Pub. Date: Mar. 19, 2009 (54) CLOBETASOL PROPIONATE SHAMPOOS Related U.S. Application Data FOR THE TREATMENT OF SEBORRHEC DERMATITS OF THE SCALP (63) Continuation of application No. 11/017.665, filed on Dec. 22, 2004, now abandoned. (76) Inventors: Florence Bistuer, NICE (FR): Publication Classification Christian Loesche, Valbonne (FR); Pascale Soto, Antibes (FR) (51) Int. Cl. A 6LX 3/575 (2006.01) Correspondence Address: A6IP 700 (2006.01) BUCHANAN, INGERSOLL & ROONEY PC (52) U.S. Cl. ......................................... 514/171; 514/178 POST OFFICE BOX 1404 ALEXANDRIA, VA 22313-1404 (US) (57) ABSTRACT Seborrheic dermatitis is effectively/safely treated by topically (21) Appl. No.: 12/235,022 applying a corticosteroid shampoo, notably a clobetasol pro pionate shampoo, onto the scalp of a human Subject afflicted (22) Filed: Sep. 22, 2008 therewith. Patent Application Publication Mar. 19, 2009 Sheet 1 of 3 US 2009/0075958A1 Figure 1: Mean percent decrease of the Total Severity Score at week 4lendpoint *: p30,01 vs 100 - vehicle k k k 2 75 - 9. s 5 50 - O) 2 5 25of E CD d O - - clobetasol clobetasol clobetasol ketoconazole 5 clobetasol propionate 10 propionate 5 min propionate 2,5 min propionate min min vehicle 10 min Patent Application Publication Mar. 19, 2009 Sheet 2 of 3 US 2009/0075958A1 Figure 2: Itching score at baseline and after 4 weeks of treatment 60 - 2 clobetasol propionate 10 min clobetasol propionate 5 min 50 - Esclobetasol propionate 2,5 min ketoconazole 5 m in 40 - Oclobetasol propionate vehicle 10 min 9) O 3 "p<0,05 vs vehicle E 30 - 8 s 20 - 10 - O baseline week 4/endpoint Patent Application Publication Mar.
    [Show full text]
  • Poisons List (Jersey) Order, 1986. ______
    1 Jersey R & O 7526 Pharmacy, Poisons and Medicines (Jersey) Law, 1952. ____________ POISONS LIST (JERSEY) ORDER, 1986. ____________ THE PUBLIC HEALTH COMMITTEE, in pursuance of Article 15 of the Pharmacy, Poisons and Medicines (Jersey) Law, 1952, as amended,1 hereby orders as follows – 1. The list of substances which are to be treated as poisons for the purposes of the Pharmacy, Poisons and Medicines (Jersey) Law, 1952,2 shall be as set out in the Schedule to this Order. 2. The Poisons List (Jersey) Order, 1969,3 the Poisons List (Amendment) (Jersey) Order, 1972,4 the Poisons List (Amendment No. 2) (Jersey) Order, 19745 and the Poisons List (Amendment No. 3) (Jersey) Order, 19756 are revoked. 3. This Order may be cited as the Poisons List (Jersey) Order, 1986 and shall come into force forthwith. By Order of the Public Health Committee, E.J.M. POTTER Greffier of the States. 23rd July, 1986. 1 Recueil des Lois, Tome VIII, page 125. 2 Recueil des Lois, Tome VIII, page 111. 3 No. 5220. 4 No. 5706. 5 No. 6046. 6 No. 6109. 2 Jersey R & O 7526 Poisons List (Jersey) Order, 1986 SCHEDULE (Article 1) THE POISONS LIST PART I (Poisons which, subject to the provisions of the Pharmacy, Poisons and Medicines (Jersey) Law, 1952, are not to be sold except by a person who is an authorised seller of poisons.) Acebutolol Hydrochloride Acetanilide; alkyl acetanilides Acetarsol Acetazolamide Sodium Acetazolamide Acetohexamide Acetorphine; its salts; its esters and ethers; their salts Acetylcarbromal Acetylcholine Chloride Acetylcysteine Acetyldigitoxin Acetyldihydrocodeine;
    [Show full text]
  • Allergic Cutaneous Reactions to Systemic Corticosteroids* Reações Cutâneas Alérgicas a Corticóides Sistêmicos* Raymond Ramirez 1 Ronald R
    169 Artigo de Revisão Allergic cutaneous reactions to systemic corticosteroids* Reações cutâneas alérgicas a corticóides sistêmicos* Raymond Ramirez 1 Ronald R. Brancaccio 2 Abstract: Contact allergic reactions to topical corticosteroids are common. Cutaneous hypersensitivity reactions to systemically administered corticosteroids might occur though less frequently. The purpose of this literature review is to examine reported cases of cutaneous reactions to systemically administered corticosteroids. The data are presented considering route of administration, type of drug, type of reac- tion, and testing results. Corticosteroid classifications, cross-reactions, and allergy testing methods are also discussed. Keywords: Adrenal cortex hormones; Adrenal cortex hormones/adverse effects; Betamethasone; Hydrocortisone; Hypersensitivity; Intradermal tests; Prednisolone; Prednisone; Triamcinolone; Patch tests Reumo: São comuns as reações alérgicas de contato a corticóides tópicos. Podem ocorrer reações cutâneas de hipersensibilidade a corticóides sistêmicos, mas são menos frequentes. O objetivo desta revisão da literatura é examinar relatos de casos de reações cutâneas a corticóides sistêmicos. Os dados apresentados levam em consideração a via de administração, tipo de medicamento, tipo de reação e resultados dos testes. A revisão discute também sobre classificações de corticóides, reações cruzadas e testes alérgicos. Palavras-chave: Betametasona; Corticosteróides; Corticosteróides/efeitos adversos; Hidrocortisona; Hipersensibilidade; Prednisolona;
    [Show full text]